Yeh M-K, Coombes A G A, Chen J-L, Chiang C-H
Department of Pediatric, and Clinical Pharmacy Research Laboratory, Room 6345, Department of Medical Research, Tri-service General Hospital, National Defence Medical Center, Taipei, Taiwan, ROC.
J Microencapsul. 2002 Sep-Oct;19(5):671-82. doi: 10.1080/02652040210142551.
Japanese encephalitis virus (JEV)-loaded poly(lactide) (PLA) lamellar and poly(DL-lactide-co-glycolide) (PLG) microparticles were successfully prepared with low molecular weight PLA by the precipitate method and with 6% w/v PLG in the organic phase, 10% w/v PVP and 5% w/v NaCl in the continuous phase, by using a water-in-oil-in-water emulsion/solvent extraction technique, respectively. JEV was entrapped in the PLG microparticles by a solvent extraction technique with trapping efficiencies up to 98%, loading level 5.5% w/w, and mean particle size 3.8 microm. The distribution (%) of JEV on the PLG microparticles surface, outer layer, and core were 11.2, 41.7 and 46.4%, respectively. The cumulative release of JEV had an upper limit of approximately 58% of the JEV load at 24 days. The steady release rate was 1.33 microg JEV/mg microparticles/day of JEV release maintained for 24 days. The corresponding virus loading of the PLA lamellae is approximately 0.78% w/w and the loading efficiency (77.8%), JEV content (7.84 microg/mg), and yield (96.3%), respectively. The distribution (%) of JEV on the microparticles surface, outer layer, and core were 82.1, 13.3 and 2.2%, respectively. The live JEV challenge in mice test, in which mice received one dose of 20 mg JEV-loaded PLG microparticles, 20 mg JEV-loaded PLA lamellar in comparison with JEV or PBS solution, was evaluated after IP immunization of BALB/c mice. The study results show that the greatest survival was observed in the group of mice immunized with 20 mg JEV-loaded PLG microparticles and 20 mg JEV-loaded PLA microparticles group (80%). The JEV incorporation, physicochemical characterization data, and the animal results obtained in this study may be relevant in optimizing the vaccine incorporation and delivery properties of these potential vaccine targeting carriers.
采用沉淀法,以低分子量聚乳酸(PLA)成功制备了负载日本脑炎病毒(JEV)的PLA层状微粒;采用水包油包水乳液/溶剂萃取技术,分别在有机相中使用6%(w/v)的聚(DL-丙交酯-共-乙交酯)(PLG)、在连续相中使用10%(w/v)的聚乙烯吡咯烷酮(PVP)和5%(w/v)的氯化钠,成功制备了负载JEV的PLG微粒。通过溶剂萃取技术将JEV包封在PLG微粒中,包封效率高达98%,载药量为5.5%(w/w),平均粒径为3.8微米。JEV在PLG微粒表面、外层和核心的分布(%)分别为11.2、41.7和46.4%。JEV的累积释放量在24天时达到JEV载量的约58%的上限。稳定释放速率为1.33微克JEV/毫克微粒/天,JEV释放持续24天。PLA层状微粒的相应病毒载量分别约为0.78%(w/w)、包封效率(77.8%)、JEV含量(7.84微克/毫克)和产率(96.3%)。JEV在微粒表面、外层和核心的分布(%)分别为82.1、13.3和2.2%。在对BALB/c小鼠进行腹腔免疫后,对小鼠进行活JEV攻击试验,比较小鼠接受一剂20毫克负载JEV的PLG微粒、20毫克负载JEV的PLA层状微粒与JEV或磷酸盐缓冲盐水(PBS)溶液后的情况。研究结果表明,在接受20毫克负载JEV的PLG微粒和20毫克负载JEV的PLA微粒免疫的小鼠组中观察到最高存活率(80%)。本研究中获得的JEV包封情况、物理化学表征数据以及动物实验结果可能与优化这些潜在疫苗靶向载体的疫苗包封和递送特性相关。